17
Sep
2025
Predicting Leukemia Risk At Scale: Dr. Lachelle Weeks on The Long Run
Dr. Lachelle Weeks is today’s guest on The Long Run. Lachelle is a physician-scientist in the adult leukemia program at Dana-Farber Cancer Institute in Boston. She treats patients who have precursors to myeloid cancers such as acute myeloid leukemia. Her research is looking at ways to detect the early warning signs of blood cancer early, when these malignancies are most... Read More
17
Sep
2025
Arch-Backed Ollin Secures $100M For Bispecific Antibodies for Eye Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Sep
2025
First CinCor, Now AllRock: Versant, Westlake Pump $50M Into PAH Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Sep
2025
An IPO Revival, Novartis Buys Tourmaline, & Tribute to a Biology Pioneer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2025
Next Stop: Kilimanjaro 2026 for Damon Runyon Cancer Research
The biotech industry can do amazing things when focused on an audacious goal. Like curing cancer. I’m fired up to announce the next Timmerman Traverse for Damon Runyon Cancer Research Foundation. This group of 23 biotech executives and investors are training to hike up to the summit of Kilimanjaro, the highest peak in Africa (elev. 19,341 feet), in February 2026.... Read More
4
Sep
2025
Atlas Adds $400M, Kite Buys In Vivo CAR-T Company, & AbbVie Bets on Psychedelics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Sep
2025
Corsera Health, Led by Maraganore and Meanwell, Aims to Prevent Heart Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Aug
2025
Creating Lower Cost, Accessible Cell & Gene Therapies: Jen Adair on The Long Run
Jen Adair is today’s guest on The Long Run. Jen is a professor and Vice Chair in the Department of Genetic and Cellular Medicine, and Associate Director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School. Her laboratory develops tools and methods for safe and effective delivery of gene therapy. In this conversation, you’ll hear... Read More
24
Aug
2025
Timmerman Traverse for Life Science Cares Raises Another $1.1M to Fight Poverty in 2025
Another Timmerman Traverse for Life Science Cares is in the books. This year, we raised $1.15 million from more than 1,000 donors to fight poverty in biotech hubs around the US. We raised awareness of worthy nonprofits close to home, through Life Science Cares. Perhaps most importantly, we had an unforgettable life experience, making friends amid some of the most... Read More
14
Aug
2025
OrbiMed’s Royalty Fund, Strand Advances IL-12 mRNA, & Melinta’s Turnaround
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2025
CAR-T Cells Against Solid Tumors: Sabah Oney on The Long Run
Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tumors. The goal is to bring the power of CAR-T cell cures to a wider group of patients, beyond those with blood cancers. Dispatch was founded by some of the... Read More
5
Aug
2025
VIDEO: Phil Sharp and Bill Haney on ‘Cracking the Code’
Science and society have always had an uneasy relationship. Yet there are always people out there seeking to build bridges of understanding. I recently moderated a conversation at MIT with Phil Sharp, the Nobel Prize-winning biologist, and Bill Haney, a filmmaker and biotech entrepreneur with Dragonfly Therapeutics and Skyhawk Therapeutics. They collaborated on a documentary film called “Cracking the Code.”... Read More
31
Jul
2025
GSK Doubles Down on China, Sarepta Rebounds, and Frazier’s $1.3B Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jul
2025
Sarepta Crashes, Abivax Soars, & Sanofi Buys Another Vaccine Platform
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jul
2025
Creative Ways to Back Young Scientists: Andy Rachleff and Yung Lie on The Long Run
Yung Lie and Andy Rachleff are today’s guests on The Long Run. Yung is the president and CEO of the Damon Runyon Cancer Research Foundation, based in New York. Andy is the board chair. Andy was one of the founding partners of Benchmark Capital, the prominent Silicon Valley VC firm, and today is the chairman of Wealthfront. This is a... Read More
22
Jul
2025
Avalyn Pharma Gets $100M to Deliver Inhalable Pulmonary Fibrosis Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jul
2025
Omega Funds, Delivering New Products and Returns, Secures $647M New Fund
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
Merck Bets $10B on COPD, AbbVie Buys In Vivo CAR-T, & FDA Transparency
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2025
5AM-Founded Renasant Bio Secures $54.5M Seed for ADPKD Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Jul
2025
A Two-Pronged Attack on Cancer: Claire Mazumdar on The Long Run
Claire Mazumdar is today’s guest on The Long Run. She is the founding CEO of Boston-based Bicara Therapeutics. Bicara is developing a bifunctional antibody for head and neck cancer. It’s called ficerafusp alfa, and it’s designed to bind with a couple of well-known biological targets, EGFR and TGF-beta. The idea is to block a well-known cancer driver in EGFR, while... Read More